A Dumortier

406 total citations
17 papers, 344 citations indexed

About

A Dumortier is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A Dumortier has authored 17 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A Dumortier's work include Cancer Treatment and Pharmacology (7 papers), Cancer therapeutics and mechanisms (5 papers) and Lung Cancer Research Studies (4 papers). A Dumortier is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Cancer therapeutics and mechanisms (5 papers) and Lung Cancer Research Studies (4 papers). A Dumortier collaborates with scholars based in France, Belgium and Netherlands. A Dumortier's co-authors include G. Catimel, Jean‐Paul Guastalla, M. Clavel, C Ardiet, Thomas Bachelot, Thierry Philip, Franck Chauvin, Isabelle Ray‐Coquard, Droz Jp and A. Mathieu-Boué and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and Journal of Affective Disorders.

In The Last Decade

A Dumortier

17 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A Dumortier France 10 226 125 61 39 33 17 344
Charles H. F. Gimbrère Netherlands 7 214 0.9× 107 0.9× 125 2.0× 42 1.1× 54 1.6× 8 719
Clara Varricchio Italy 11 272 1.2× 255 2.0× 181 3.0× 77 2.0× 56 1.7× 22 525
Michelle Geller United States 8 153 0.7× 108 0.9× 65 1.1× 32 0.8× 102 3.1× 13 466
Zhimin Yang China 11 129 0.6× 72 0.6× 52 0.9× 86 2.2× 31 0.9× 25 397
K. I. Pritchard Canada 8 247 1.1× 75 0.6× 82 1.3× 95 2.4× 25 0.8× 25 563
Lynn Adams United States 8 209 0.9× 80 0.6× 36 0.6× 95 2.4× 52 1.6× 9 376
Aviva G. Asnis-Alibozek United States 5 170 0.8× 68 0.5× 117 1.9× 131 3.4× 23 0.7× 7 489
Shaily Arora United States 8 164 0.7× 103 0.8× 51 0.8× 43 1.1× 25 0.8× 12 373
Lisel Koepl United States 11 156 0.7× 58 0.5× 33 0.5× 87 2.2× 33 1.0× 12 325
Amandine Gouverneur France 12 121 0.5× 121 1.0× 19 0.3× 60 1.5× 63 1.9× 28 454

Countries citing papers authored by A Dumortier

Since Specialization
Citations

This map shows the geographic impact of A Dumortier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Dumortier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Dumortier more than expected).

Fields of papers citing papers by A Dumortier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A Dumortier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Dumortier. The network helps show where A Dumortier may publish in the future.

Co-authorship network of co-authors of A Dumortier

This figure shows the co-authorship network connecting the top 25 collaborators of A Dumortier. A scholar is included among the top collaborators of A Dumortier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A Dumortier. A Dumortier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Bachelot, Thomas, F. Gómez, Pierre Biron, et al.. (2002). A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients. British Journal of Cancer. 87(10). 1079–1085. 2 indexed citations
2.
Bachelot, Thomas, Isabelle Ray‐Coquard, G. Catimel, et al.. (2000). Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Annals of Oncology. 11(2). 151–156. 98 indexed citations
3.
Quantin, Xavier, et al.. (2000). A phase I–II study of docetaxel (D) and gemcitabine (G) combination in patients (pts) with non-small cell lung cancer (NSCLC). Lung Cancer. 29(1). 103–103. 3 indexed citations
4.
Zanetta, Sylvie, Aline Guillot, C Ardiet, et al.. (1999). A dose finding and pharmacokinetic study of docetaxel (TXT) and methotrexate (MTX) in patients with epithelial cancer. European Journal of Cancer. 35. S288–S288. 2 indexed citations
5.
Tranchand, Brigitte, G. Catimel, Catherine Lucas, et al.. (1998). Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 41(4). 281–291. 23 indexed citations
6.
Dumortier, A, et al.. (1997). [Efficacy of massage and mobilization of the upper limb after surgical treatment of breast cancer].. PubMed. 84(10). 957–61. 21 indexed citations
7.
Catimel, G., M. Spielmann, M. Tubiana-Hulin, et al.. (1997). Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.. PubMed. 24(1 Suppl 3). S8–12. 6 indexed citations
8.
Catimel, G., M. Spielmann, L. Kayitalire, et al.. (1996). Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.. PubMed. 23(1 Suppl 1). 24–7. 24 indexed citations
9.
Catimel, G., et al.. (1995). Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors. Cancer Chemotherapy and Pharmacology. 35(3). 246–248. 15 indexed citations
10.
Catimel, G., G G Chabot, Jean‐Paul Guastalla, et al.. (1995). Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Annals of Oncology. 6(2). 133–140. 94 indexed citations
11.
Dirix, Luc, G. Catimel, A. Prové, et al.. (1995). Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149. Anti-Cancer Drugs. 6(1). 53–63. 13 indexed citations
12.
13.
Merrouche, Yacine, G. Catimel, Paul Rebattu, et al.. (1994). A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Annals of Oncology. 5(6). 549–551. 9 indexed citations
14.
Giaccone, Giuseppe, S. C. Linn, G. Catimel, et al.. (1994). SDZ PSC 833 in combination with doxorubicin. Anti-Cancer Drugs. 5. 42–42. 9 indexed citations
15.
Guastalla, Jean Paul, et al.. (1994). Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors. Cancer Chemotherapy and Pharmacology. 35(3). 246–248. 2 indexed citations
16.
Dumortier, A, A. Prové, D. Schrijvers, et al.. (1993). A phase I and pharmacokinetic trial of KW-2149, a mitomycin C analogue, in patients with solid tumours. European Journal of Cancer. 29. S118–S118. 1 indexed citations
17.
Ansseau, M., et al.. (1984). Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depression. Journal of Affective Disorders. 7(3-4). 287–296. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles H. F. Gimbrère Breakdown of academic impact, for papers by Clara Varricchio Breakdown of academic impact, for papers by Michelle Geller Breakdown of academic impact, for papers by Zhimin Yang Breakdown of academic impact, for papers by K. I. Pritchard Breakdown of academic impact, for papers by Lynn Adams Breakdown of academic impact, for papers by Aviva G. Asnis-Alibozek Breakdown of academic impact, for papers by Shaily Arora Breakdown of academic impact, for papers by Lisel Koepl Breakdown of academic impact, for papers by Amandine Gouverneur
Rankless by CCL
2026